CL2018000805A1 - Compuestos terapéuticos y sus métodos de uso. - Google Patents

Compuestos terapéuticos y sus métodos de uso.

Info

Publication number
CL2018000805A1
CL2018000805A1 CL2018000805A CL2018000805A CL2018000805A1 CL 2018000805 A1 CL2018000805 A1 CL 2018000805A1 CL 2018000805 A CL2018000805 A CL 2018000805A CL 2018000805 A CL2018000805 A CL 2018000805A CL 2018000805 A1 CL2018000805 A1 CL 2018000805A1
Authority
CL
Chile
Prior art keywords
methods
therapeutic compounds
compounds
ring
compositions
Prior art date
Application number
CL2018000805A
Other languages
English (en)
Inventor
Sultan Chowdhury
Brian Safina
Christoph Martin Dehnhardt
Michael Edward Grimwood
Zhiguo Liu
Daniel Sutherlin
Phillipe Bergeron
Kristen Burford
Thilo Focken
Abid Hasan
Kwong Wah Lai
Steven Mckerrall
Teresa Phuongtram Nguyen
Tao Wang
Original Assignee
Genentech Inc
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Xenon Pharmaceuticals Inc filed Critical Genentech Inc
Publication of CL2018000805A1 publication Critical patent/CL2018000805A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)

Abstract

<p>LA INVENCIÓN PROPORCIONA UN COMPUESTO DE FÓRMULA, O UNA SAL DE ESTE, DONDE LAS VARIABLES RAA, N, ANILLO A, ANILLO B, Rlb, Rla, R2, R3, R4, R5, R6, R7, R8 y R9 TIENEN EL SIGNIFICADO DESCRITO EN LA PRESENTE Y COMPOSICIONES QUE CONTIENEN ESTOS COMPUESTOS Y MÉTODOS PARA USAR TALES COMPUESTOS Y COMPOSICIONES. </p>
CL2018000805A 2015-09-28 2018-03-28 Compuestos terapéuticos y sus métodos de uso. CL2018000805A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233863P 2015-09-28 2015-09-28
US201662298817P 2016-02-23 2016-02-23
CN2016096659 2016-08-25

Publications (1)

Publication Number Publication Date
CL2018000805A1 true CL2018000805A1 (es) 2018-07-06

Family

ID=57137267

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000805A CL2018000805A1 (es) 2015-09-28 2018-03-28 Compuestos terapéuticos y sus métodos de uso.

Country Status (21)

Country Link
US (2) US10787446B2 (es)
EP (1) EP3356360A1 (es)
JP (1) JP6987746B2 (es)
KR (1) KR20180067561A (es)
CN (1) CN108290881B (es)
AU (1) AU2016330503B2 (es)
BR (1) BR112018006189A2 (es)
CA (1) CA2999769A1 (es)
CL (1) CL2018000805A1 (es)
CO (1) CO2018003909A2 (es)
CR (1) CR20180242A (es)
HK (1) HK1258056A1 (es)
IL (1) IL258192A (es)
MX (1) MX2018003828A (es)
PE (1) PE20181003A1 (es)
PH (1) PH12018500668A1 (es)
RU (1) RU2018115718A (es)
SG (1) SG10202007787RA (es)
TW (1) TWI726916B (es)
WO (1) WO2017058821A1 (es)
ZA (1) ZA201802134B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110546148A (zh) * 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
CN112321494B (zh) * 2020-11-17 2022-04-19 上海凌凯医药科技有限公司 一种制备2-氯-4-异丙基吡啶的方法
WO2023028056A1 (en) * 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705185A (en) 1969-04-14 1972-12-05 Minnesota Mining & Mfg N-aroyl sulfonamides
JPS59140445A (ja) * 1983-01-31 1984-08-11 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
US5096771A (en) 1988-07-14 1992-03-17 General Electric Company Fibers impregnated with epoxy resin mixture, brominated bisphenol and polyphenylene ether
DK24089D0 (da) 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
GB8904174D0 (en) * 1989-02-23 1989-04-05 British Bio Technology Compounds
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
DK0669920T3 (da) 1992-11-23 2003-05-26 Aventis Pharma Inc Substituerede 3-(aminoalkylamino)-1,2-benzisoxazoler og beslægtede forbindelser
US5573653A (en) 1994-07-11 1996-11-12 Sandoz Ltd. Electrochemical process for thiocyanating aminobenzene compounds
GB9510477D0 (en) 1995-05-24 1995-07-19 Sandoz Ltd Organic compounds
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
NZ333322A (en) * 1996-07-01 2000-06-23 Schering Corp Di-N-substituted piperazines and 1,4-di-substituted piperidines as muscarinic antagonists
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
KR100789567B1 (ko) 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
DE10201550A1 (de) 2002-01-17 2003-07-31 Merck Patent Gmbh Phenoxy-Piperidine
WO2004014913A2 (en) 2002-08-08 2004-02-19 Memory Pharmaceuticals Corporation Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
CA2521915A1 (en) 2003-04-15 2004-10-28 Pfizer Inc. Alpha substituted carboxylic acid as ppar modulators
CA2539227A1 (en) 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
CN1863785A (zh) 2003-08-08 2006-11-15 沃泰克斯药物股份有限公司 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物
KR20060113700A (ko) 2003-10-03 2006-11-02 포톨라 파마슈티컬스, 인코포레이티드 2,4-디옥소-3-퀴나졸리닐아릴 설포닐우레아
US7081539B2 (en) 2004-03-25 2006-07-25 Dainippon Sumitomo Pharma Co., Ltd. One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide
CN1993335A (zh) 2004-07-30 2007-07-04 默克公司 代谢型谷氨酸受体的二氢茚酮增效剂
US7544702B2 (en) 2004-08-12 2009-06-09 Amgen Inc. Bisaryl-sulfonamides
US7205296B2 (en) 2004-09-29 2007-04-17 Portola Pharmaceuticals, Inc. Substituted 2H-1,3-benzoxazin-4(3H)-ones
CN101277949A (zh) * 2005-04-22 2008-10-01 阿兰托斯制药控股公司 二肽基肽酶-ⅳ抑制剂
CN101218235A (zh) 2005-05-10 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
JP2008189549A (ja) 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7915410B2 (en) 2005-09-09 2011-03-29 Bristol-Myers Squibb Company Acyclic IKur inhibitors
EP1940782B1 (en) 2005-10-19 2009-03-11 F.Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors
JP2009519352A (ja) 2005-11-23 2009-05-14 リガンド・ファーマシューティカルズ・インコーポレイテッド トロンボポエチン活性調節化合物および方法
AR058296A1 (es) 2005-12-09 2008-01-30 Kalypsys Inc Inhibidores de histona desacetilasa y composicion farmaceutica
KR20080109918A (ko) 2006-04-11 2008-12-17 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물
ES2377821T3 (es) 2006-10-11 2012-04-02 Amgen Inc. Compuestos de imidazo- y triazolo-piridina y métodos de uso de los mismos.
WO2008094575A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-h-pyrazolo(3,4b)pyrimidine derivatives and their use as modulators of mitotic kinases
US20080194616A1 (en) 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
WO2008109154A1 (en) * 2007-03-08 2008-09-12 Altiris Therapeutics, Inc. Chemokine receptor modulators
WO2008118758A1 (en) 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels
EP2158183A2 (en) 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
CN101679262A (zh) 2007-06-07 2010-03-24 安斯泰来制药株式会社 吡啶酮化合物
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
TW200911766A (en) 2007-07-13 2009-03-16 Astrazeneca Ab New compounds
EP2184278A4 (en) 2007-08-10 2011-08-03 Nippon Chemiphar Co P2X4 RECEIVER ANTAGONIST
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
EP2234487A4 (en) * 2007-12-19 2011-09-07 Scripps Research Inst ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
SI2262778T1 (sl) * 2008-03-07 2019-12-31 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, na osnovi izražanja MCP-1, CXCR1 in P40
US8314240B2 (en) 2008-06-23 2012-11-20 Astellas Pharma Inc. Sulfonamide compounds or salts thereof
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
RS56410B1 (sr) 2009-07-27 2018-01-31 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
WO2011016234A1 (en) 2009-08-04 2011-02-10 Raqualia Pharma Inc. Picolinamide derivatives as ttx-s blockers
TW201117809A (en) 2009-09-25 2011-06-01 Astellas Pharma Inc Substituted amide compounds
WO2011059042A1 (ja) 2009-11-12 2011-05-19 武田薬品工業株式会社 芳香環化合物
US8471034B2 (en) 2009-11-18 2013-06-25 Concert Pharmaceuticals, Inc. Niacin prodrugs and deuterated versions thereof
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US8759548B2 (en) 2010-02-12 2014-06-24 N30 Pharmaceuticals, Inc. S-nitrosoglutathione reductase inhibitors
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
WO2012005842A1 (en) 2010-06-30 2012-01-12 Cardiac Pacemakers, Inc. Lead having coil electrode with preferential bending region
US9279003B2 (en) 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
EP2590951B1 (en) 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
CA2803118C (en) 2010-07-09 2015-11-03 Pfizer Limited Sulfonamide derivatives as nav 1.7 inhibitors
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2012007877A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
WO2012007869A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
WO2012007836A1 (en) 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
PE20131377A1 (es) 2010-09-13 2013-11-30 Novartis Ag Triazina-oxadiazoles
WO2012039657A1 (en) 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
AU2011346751A1 (en) 2010-12-22 2013-05-02 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
AR085893A1 (es) 2011-02-02 2013-11-06 Vertex Pharma Pirrolopirazina-amidas de piperidina espirociclica como moduladores de los canales ionicos
WO2013025883A1 (en) 2011-08-17 2013-02-21 Amgen Inc. Heteroaryl sodium channel inhibitors
US20140235676A1 (en) 2011-10-13 2014-08-21 Case Western Reserve University Rxr agonist compounds and methods
JP2014532660A (ja) 2011-10-28 2014-12-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
EP2788332A1 (en) * 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
WO2013102826A1 (en) 2012-01-04 2013-07-11 Pfizer Limited N-aminosulfonyl benzamides
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
WO2013146969A1 (ja) 2012-03-29 2013-10-03 第一三共株式会社 新規二置換シクロヘキサン誘導体
US8952169B2 (en) 2012-05-22 2015-02-10 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
TW201416362A (zh) 2012-07-19 2014-05-01 Dainippon Sumitomo Pharma Co １－（環烷基羰基）脯胺酸衍生物
WO2014066491A1 (en) 2012-10-26 2014-05-01 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
BR112015009216A2 (pt) 2012-10-26 2017-07-04 Merck Sharp & Dohme composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
PE20151781A1 (es) 2013-01-31 2015-12-02 Vertex Pharma Piridonamidas como moduladores de canales de sodio
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
KR20150131233A (ko) 2013-03-14 2015-11-24 제넨테크, 인크. 치환된 트리아졸로피리딘 및 이의 사용 방법
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
BR112015022096A8 (pt) 2013-03-15 2019-11-26 Chromocell Corp compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
WO2015051043A1 (en) 2013-10-01 2015-04-09 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
JP6383418B2 (ja) 2013-11-27 2018-08-29 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
JP2018520107A (ja) 2015-05-22 2018-07-26 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
CN110546148A (zh) * 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物

Also Published As

Publication number Publication date
WO2017058821A1 (en) 2017-04-06
CN108290881B (zh) 2021-12-07
ZA201802134B (en) 2020-08-26
JP2018533551A (ja) 2018-11-15
JP6987746B2 (ja) 2022-01-05
CR20180242A (es) 2018-08-10
AU2016330503A1 (en) 2018-04-12
PH12018500668A1 (en) 2018-10-01
HK1258056A1 (zh) 2019-11-01
BR112018006189A2 (pt) 2018-10-09
SG10202007787RA (en) 2020-09-29
US10787446B2 (en) 2020-09-29
TW201718556A (zh) 2017-06-01
RU2018115718A (ru) 2019-10-28
CO2018003909A2 (es) 2018-07-19
EP3356360A1 (en) 2018-08-08
MX2018003828A (es) 2018-06-22
US20180291014A1 (en) 2018-10-11
AU2016330503B2 (en) 2021-04-08
US20210171516A1 (en) 2021-06-10
IL258192A (en) 2018-05-31
KR20180067561A (ko) 2018-06-20
PE20181003A1 (es) 2018-06-26
CN108290881A (zh) 2018-07-17
TWI726916B (zh) 2021-05-11
RU2018115718A3 (es) 2019-12-27
AU2016330503A8 (en) 2018-04-19
CA2999769A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
CO2020000633A2 (es) Compuestos macrocíclicos y usos de los mismos
CL2018000293A1 (es) Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa
CR20140578A (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CR20160296A (es) Benzamidas sustituidas y métodos para usarlas
CO2017005995A2 (es) Composiciones para el cuidado bucal y métodos de uso
CO2017003279A2 (es) Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
DOP2017000178A (es) Inhibidores selectivos de bace1
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2016000568A1 (es) Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas.
ECSP17069696A (es) Compuestos novedosos
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
CL2018000805A1 (es) Compuestos terapéuticos y sus métodos de uso.
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
DOP2017000036A (es) Compuestos de azetidiniloxifenilpirrolidina
TH1801001902A (th) สารประกอบที่ใช้ในการบำบัดโรคและวิธีการใช้สารเหล่านั้น
CR20160175A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa